Article info
PDFPostScript
Letter
Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients
- Correspondence to Dr Richard J Nowak, Department of Neurology, Division of Neuromuscular Medicine, Yale University School of Medicine, PO Box 208018, 15 York Street, LCI 9th floor, New Haven, CT 06510, USA; richard.nowak{at}yale.edu
Citation
Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients
Publication history
- Received July 12, 2012
- Revised February 6, 2013
- Accepted May 15, 2013
- First published June 12, 2013.
Online issue publication
April 13, 2016
Article Versions
- Previous version (13 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions